Upstream Bio, Inc. (NASDAQ:UPB) Receives $33.17 Average Price Target from Brokerages

Upstream Bio, Inc. (NASDAQ:UPB) has been given an average rating of “Hold” by the seven analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $33.1667.

A number of brokerages recently issued reports on UPB. JPMorgan Chase & Co. lowered Upstream Bio from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $35.00 to $8.00 in a research note on Friday, June 12th. HC Wainwright initiated coverage on Upstream Bio in a report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price objective on the stock. Mizuho reduced their price objective on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Upstream Bio in a report on Monday.

Institutional Trading of Upstream Bio

Several institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. lifted its position in Upstream Bio by 6.4% during the second quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock valued at $179,000 after purchasing an additional 985 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Upstream Bio during the 4th quarter worth about $29,000. Torren Management LLC purchased a new position in shares of Upstream Bio during the 4th quarter valued at about $30,000. JPMorgan Chase & Co. raised its stake in shares of Upstream Bio by 8.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after buying an additional 1,275 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of Upstream Bio by 83.0% in the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after buying an additional 1,440 shares during the period.

Upstream Bio Trading Up 1.9%

NASDAQ:UPB opened at $6.87 on Friday. The company has a market cap of $373.87 million, a PE ratio of -2.36 and a beta of 1.26. Upstream Bio has a twelve month low of $5.85 and a twelve month high of $33.68. The company’s 50 day moving average is $6.87 and its two-hundred day moving average is $10.76.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%.The company had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $1.03 million. As a group, analysts expect that Upstream Bio will post -2.9 EPS for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.